- Home
- DAWN vs EVT Comparison
DAWN vs EVT Comparison
Compare DAWN & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- EVT
- Stock Information
- Founded
- DAWN 2018
- EVT 2003
- Country
- DAWN United States
- EVT United States
- Employees
- DAWN N/A
- EVT N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- DAWN Health Care
- EVT Finance
- Exchange
- DAWN Nasdaq
- EVT Nasdaq
- Market Cap
- DAWN 1.6B
- EVT 1.8B
- IPO Year
- DAWN 2021
- EVT N/A
- Fundamental
- Price
- DAWN $13.72
- EVT $25.30
- Analyst Decision
- DAWN Strong Buy
- EVT
- Analyst Count
- DAWN 7
- EVT 0
- Target Price
- DAWN $36.17
- EVT N/A
- AVG Volume (30 Days)
- DAWN 1.3M
- EVT 121.5K
- Earning Date
- DAWN 10-30-2024
- EVT 01-01-0001
- Dividend Yield
- DAWN N/A
- EVT 7.72%
- EPS Growth
- DAWN N/A
- EVT N/A
- EPS
- DAWN N/A
- EVT N/A
- Revenue
- DAWN $101,953,000.00
- EVT N/A
- Revenue This Year
- DAWN N/A
- EVT N/A
- Revenue Next Year
- DAWN $44.21
- EVT N/A
- P/E Ratio
- DAWN N/A
- EVT N/A
- Revenue Growth
- DAWN N/A
- EVT N/A
- 52 Week Low
- DAWN $11.30
- EVT $18.70
- 52 Week High
- DAWN $18.07
- EVT $23.82
- Technical
- Relative Strength Index (RSI)
- DAWN 43.29
- EVT 63.33
- Support Level
- DAWN $12.86
- EVT $24.86
- Resistance Level
- DAWN $13.71
- EVT $25.22
- Average True Range (ATR)
- DAWN 0.75
- EVT 0.21
- MACD
- DAWN -0.21
- EVT 0.03
- Stochastic Oscillator
- DAWN 21.99
- EVT 93.85
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.